Skip to main content

Advertisement

SpringerLink
Log in

Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer

  • Original Article
  • Published:
Tumor Biology

Abstract

Chemotherapy remains the first-choice option for adjuvant therapy in breast cancer. Here, we investigated the impact of the first chemotherapic cycle of doxorubicin on the plasmatic–proteomic profiling of women diagnosed with breast cancer (n = 87). Blood samples were obtained from the same patient before and after doxorubicin infusion (1 h, 60 mg/m2) and processed for label-free LC-MS proteomic screening. A total of 80 proteins were downregulated after chemotherapy. In silico analysis revealed that the main biological process enrolled was inflammation and canonical pathways involving acute phase proteins. TNF-α, IL-1β, IL-12, TGF-β1, clusterin, and gelsolin were chosen as relevant for further validation. All selected targets presented reduced plasmatic levels after treatment. Our results indicate that doxorubicin downregulated acute phase proteins immediately after its infusion. Since such proteins are cancer promoting, its downregulation could support the effectiveness of doxorubicin along treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cecilio AP, Takakura ET, Jumes JJ, Dos Santos JW, Herrera AC, Victorino VJ, et al. Breast cancer in Brazil: epidemiology and treatment challenges. Breast Cancer. 2015;7:43–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Chew E. Adjuvant therapy for breast cancer - who should get what? West J Med. 2001;174(4):284–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Prietsman TJ. Results of a prospective clinical trial comparing two cytotoxic regimes containing adriamycin in women with advanced breast cancer. Clin Oncol. 1975;1(3):207–11.

    Google Scholar 

  4. Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel Monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol. 2009;20(27):4522–9.

    Article  CAS  Google Scholar 

  5. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.

    Article  CAS  PubMed  Google Scholar 

  6. Kim ES, Cha Y, Ham M, Jung J, Kim SG, Hwang S, et al. Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBPβ and potentiates breast cancer progression. Oncogene. 2014;33(27):3583–93.

    Article  CAS  PubMed  Google Scholar 

  7. Ham M, Moon A. Inflammatory and microenvironmental factors involved in breast cancer progression. Arch Pharm Res. 2013;36(12):1419–31.

    Article  CAS  PubMed  Google Scholar 

  8. Lakota K, Zigon P, Mrak-Poljsak K, Rozman B, Shoenfeld Y, Sodin-Semrl S. Antibodies against acute phase proteins and their functions in the pathogenesis of disease: a collective profile of 25 different antibodies. Autoimmun Rev. 2011;10(12):779–89.

    Article  CAS  PubMed  Google Scholar 

  9. Pensa S, Watson CJ, Poli V. Stat3 and the inflammation/acute phase response in involution and breast cancer. J Mammary Gland Biol Neoplasia. 2009;14(2):121–9.

    Article  PubMed  Google Scholar 

  10. Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol. 2003;1(3):159–68.

    CAS  PubMed  Google Scholar 

  11. Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP. CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med. 2009;7:102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res. 2013;56(1):131–42.

    Article  CAS  PubMed  Google Scholar 

  13. Noguchi Y, Yoshikawa T, Matsumoto A, Svaninger G, Gelin J. Are cytokines possible mediators of cancer cachexia? Surg Today. 1996;26(7):467–75.

    Article  CAS  PubMed  Google Scholar 

  14. Stephens NA, Skipworth RJ, Fearon KC. Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care. 2008;2(4):267–74.

    Article  PubMed  Google Scholar 

  15. Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, et al. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. Br J Cancer. 2010;103(8):1201–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Panis C, Pizzatti L, Herrera AC, Cecchini R, Abdelhay E. Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics. Cancer Lett. 2013;330(1):57–66.

    Article  CAS  PubMed  Google Scholar 

  17. Panis C, Pizzatti L, Herrera AC, Corrêa S, Binato R, Abdelhay E. Label-free proteomic analysis of breast cancer molecular subtypes. J Proteome Res. 2014;13(11):4752–72.

    Article  CAS  PubMed  Google Scholar 

  18. Panis C, Pizzatti L, Corrêa S, Binato R, Lemos GF, Herrera AC, et al. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Lett. 2015;357(1):186–95.

    Article  CAS  PubMed  Google Scholar 

  19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol. 2005;2(8):416–22.

    Article  CAS  PubMed  Google Scholar 

  20. Panis C, Pizzatti L, Abdelhay E. How can proteomics reach cancer biomarkers? Curr Proteomics. 2013;10(2):136–49.

    Article  CAS  Google Scholar 

  21. Pizzatti L, Panis C, Lemos G, Rocha M, Cecchini R, Souza GH, et al. Label-free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance. Proteomics. 2012;12(17):2618–31.

    Article  CAS  PubMed  Google Scholar 

  22. Chen ST, Pan TL, Tsai YC, Huang CM. Proteomics reveals protein profile changes in doxorubicin--treated MCF-7 human breast cancer cells. Cancer Lett. 2002;181(1):95–107.

    Article  CAS  PubMed  Google Scholar 

  23. Kumar SN, Konorev EA, Aggarwal D, Kalyanaraman B. Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte. J Proteomics. 2011;74(5):683–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lee SH, Kim SY, Kim JH, Jung HY, Moon JH, Bae KH, et al. Phosphoproteomic analysis of electroacupuncture analgesia in an inflammatory pain rat model. Mol Med Rep. 2012;6(1):157–62.

    CAS  PubMed  Google Scholar 

  25. Panis C. Unraveling oxidation-induced modifications in proteins by proteomics. Adv Protein Chem Struct Biol. 2014;94:19–38.

    Article  PubMed  Google Scholar 

  26. Kono H, Onda A, Yanagida T. Molecular determinants of sterile inflammation. Curr Opin Immunol. 2014;26:147–56.

    Article  CAS  PubMed  Google Scholar 

  27. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122(4):143–59.

    Article  CAS  Google Scholar 

  28. Desborough JP. The stress response to trauma and surgery. Br J Anaesth. 2000;85(1):109–17.

    Article  CAS  PubMed  Google Scholar 

  29. Panis C, Victorino VJ, Herrera AC, Freitas LF, De Rossi T, Campos FC, et al. Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat. 2012;133(3):881–8.

    Article  CAS  PubMed  Google Scholar 

  30. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754–62.

    Article  CAS  PubMed  Google Scholar 

  31. Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, Uchida A. TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun. 2011;407(3):525–30.

    Article  CAS  PubMed  Google Scholar 

  32. Yu M, Zhou X, Niu L, Lin G, Huang J, Zhou W, et al. Targeting transmembrane TNF-α suppresses breast cancer growth. Cancer Res. 2013;73(13):4061–74.

    Article  CAS  PubMed  Google Scholar 

  33. Fruehauf JP, Sinha BK. Selective formation of tumor necrosis factor-alpha (TNF) degradation products contributes to TNF mediated cytotoxicity. Oncol Res. 1992;4(3):91–101.

    CAS  PubMed  Google Scholar 

  34. Suswam EA, Nabors LB, Huang Y, Yang X, King PH. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3′ untranslated region: involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer. 2005;113(6):911–9.

    Article  CAS  PubMed  Google Scholar 

  35. Schwartz Y, Avraham R, Benish M, Rosenne E, Ben-Eliyahu S. Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells. Breast Cancer Res Treat. 2008;107(2):211–23.

    Article  CAS  PubMed  Google Scholar 

  36. Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 2014;31:56–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zarzynska JM. Two faces of TGF-beta1 in breast cancer. Mediat Inflamm. 2014;2014:141747.

    Article  CAS  Google Scholar 

  38. Falgarone G, Chiocchia G. Chapter 8: clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity. Adv Cancer Res. 2009;104:139–70.

    Article  CAS  PubMed  Google Scholar 

  39. Djeu JY, Wei S. Clusterin and chemoresistance. Adv Cancer Res. 2009;105:77–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Niu ZH, Wang Y, Chun B, Li CX, Wu L. Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. Eur Rev Med Pharmacol Sci. 2013;17(10):1337–44.

    PubMed  Google Scholar 

  41. Li GH, Arora PD, Chen Y, McCulloch CA, Liu P. Multifunctional roles of gelsolin in health and diseases. Med Res Rev. 2012;32(5):999–1025.

    Article  CAS  PubMed  Google Scholar 

  42. Van den Abbeele A, De Corte V, Van Impe K, Bruyneel E, Boucherie C, Bracke M, et al. Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett. 2007;255(1):57–70.

    Article  CAS  PubMed  Google Scholar 

  43. Buranrat B, Connor JR. Cytoprotective effects of ferritin on doxorubicin-induced breast cancer cell death. Oncol Rep. 2015. doi:10.3892/or.2015.4250.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors are grateful to the Conselho Nacional de Desenvolvimento Tecnológico (CNPq), INCT para o Controle do Câncer and Fundação Araucária for providing the financial support of the study.

Author information

Authors and Affiliations

  1. Laboratório de Células Tronco, Instituto Nacional do Câncer, INCA, Rio de Janeiro, Brazil

    Carolina Panis, Luciana Pizzatti & Eliana Abdelhay

  2. Laboratório de Mediadores Inflamatórios, Universidade Estadual do Oeste do Paraná, UNIOESTE, Francisco Beltrão, Paraná, Brazil

    Carolina Panis, Aedra Carla Bufalo & Vanessa Jacob Victorino

  3. Departamento de Bioquímica, Instituto de Química, Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, Brazil

    Luciana Pizzatti

  4. Pontifícia Universidade Católica, PUC, Londrina, Paraná, Brazil

    Ana Cristina Herrera

  5. Faculdade de Medicina, Universidade de São Paulo, USP, São Paulo, Brazil

    Vanessa Jacob Victorino

  6. Laboratório de Fisiopatologia de Radicais Livres, Universidade Estadual de Londrina, Londrina, Paraná, Brazil

    Rubens Cecchini

  7. INCT para o Controle do Câncer, Rio de Janeiro, Brazil

    Eliana Abdelhay

Authors
  1. Carolina Panis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luciana Pizzatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aedra Carla Bufalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Cristina Herrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vanessa Jacob Victorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rubens Cecchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eliana Abdelhay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carolina Panis.

Ethics declarations

Conflict of interest

None.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Table 1

(XLS 40kb)

Supplementary Table 2

(XLS 1841kb)

Supplementary Table 3

(XLS 1981kb)

Supplementary Table 4

(XLS 58kb)

Supplementary Table 5

(XLS 57kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panis, C., Pizzatti, L., Bufalo, A.C. et al. Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer. Tumor Biol. 37, 3775–3783 (2016). https://doi.org/10.1007/s13277-015-4203-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4203-7

Keywords

Search

Navigation